biologics commercialization Archives

Deals
News

Piramal Pharma Acquires Majority Stake in Yapan Bio to Expand Large-Molecule CDMO Capabilities

Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...

Ridhi Rastogi

August 19, 2026

Browsing Tag: biologics commercialization

Piramal Pharma Acquires Majority Stake in Yapan Bio to Expand Large-Molecule CDMO Capabilities

Featured Posts

ChrysCapital to Acquire Stake in Linux Laboratories

Sanofi Partners with Tricog Health to Advance AI-Powered Cardiac Diagnostics

HRV Pharma to Invest ₹150 Crore to Expand Peptide and High-Potency API Capabilities